![Desjardins RI USA Net Zero Emissions Pathway ETF](/common/images/company/T_DRMU.png)
— Strengthens global leadership in serving patients with devastating and rare diseases — — Expands premier global metabolic rare disease franchise with the addition of Kanuma™...
Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB PR Newswire LEXINGTON, Mass., June 4, 2015 LEXINGTON, Mass., June 4, 2015...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva” or "the Company") (Nasdaq:...
Synageva BioPharma Submits Kanuma™ (Sebelipase Alfa) Application For LAL Deficiency In Japan PR Newswire LEXINGTON, Mass., May 26, 2015 LEXINGTON, Mass., May 26, 2015 /PRNewswire/ -- Synageva...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp. -GEVA PR Newswire BALA CYNWYD, Pa., May 22, 2015 BALA CYNWYD, Pa., May...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synageva BioPharma Corp. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma Corp. Juan E. Monteverde, a...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Synageva BioPharma Corp. stock prior to May 6, 2015. You are hereby...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.